Search Results

CHAMPION PHOENIX Data Support Intravenous Cangrelor

March 10, 2013—The Medicines Company (Parsippany, NJ) reported results from the CHAMPION PHOENIX phase 3 clinical trial comparing the company's intravenous antiplatelet cangrelor to oral clopidogrel in patients undergoing percutaneous coronary intervention (PCI).

FDA Advisory Committee Recommends Approval of Cangrelor

April 15, 2015—The Medicines Company announced that the US Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has voted 9 to 2, with one abstention, to recommend approval of the investigational intravenous antiplatelet agent cangrelor as an adjunct to percutaneous coronary intervention (PCI) for reducing the risk of periprocedural thrombotic events, such as myocardial infarction, stent thrombosis, and ischemia-driven revascularization.

Chiesi USA’s Kengreal Evaluated in Post Hoc Analysis of CHAMPION PHOENIX

January 25, 2022—Chiesi USA announced the publication of a post hoc analysis of the CHAMPION PHOENIX clinical trial that evaluated the timing, number, and type of early cardiovascular events that occurred with treatment of the company’s Kengreal (cangrelor) compared to clopidogrel in patients undergoing percutaneous coronary intervention (PCI).

Study Shows Effectiveness of Appropriate Use Criteria for PCI

November 9, 2015—The American College of Cardiology (ACC) announced that the number of angioplasty procedures classified as rarely appropriate declined sharply between 2010 and 2014, as did the number of procedures performed on patients with nonacute conditions.

Dr. Harrington to Deliver SCAI 2015 Hildner Lecture on Future of Clinical Research

January 5, 2015—The Society for Cardiovascular Angiography and Interventions (SCAI) announced that Robert Harrington, MD, will deliver the annual Hildner lecture at the SCAI 2015 scientific sessions in San Diego, California, on May 6–9, 2015.